Oncology News | pharmaphorum

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

News

Ipsen buys ImCheck, adding mid-stage leukaemia drug

Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.

News

Takeda builds in cancer with monster $11.4bn Innovent deal

Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.

News

UK start-up Procyon has pancreatic cancer test in its sights

Procyon is hoping to launch a diagnostic test next year that will be able to detect people at risk of pancreatic cancer from a urine sample.

News

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.

Bayer's prostate cancer drug Nubeqa cleared for NHS use

GSK's Blenrep's back in US, but with a narrower label

Ipsen buys ImCheck, adding mid-stage leukaemia drug

Takeda builds in cancer with monster $11.4bn Innovent deal

UK start-up Procyon has pancreatic cancer test in its sights

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Alzheimer's biotech Korsana to go public via reverse merger

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks